Lilly registers a Chinese Phase 3 of orforglipron in obesity

Eli Lilly has filed a Phase 3 trial of orforglipron, the oral GLP-1 drug sold in the U.S. as Foundayo, for adults in China with obesity or overweight and a weight-related health problem. The trial is set to enroll 192 participants and is listed as not yet recruiting ^[1]. The filing adds China to a late-stage program that is already moving through regulatory review in more than 40 markets worldwide as of August, according to analysts at William Blair cited by BioSpace ^[2].

The move comes as the obesity drug market keeps expanding. Sales of obesity therapeutics reached $66 billion last year and could climb to somewhere between $105 billion and $200 billion by 2027, based on IQVIA estimates reported by BioSpace ^[2]. Lilly and Novo Nordisk currently dominate that market, but Novo has a head start specifically in oral pills: its Wegovy pill held about 90% of weekly oral GLP-1 prescriptions as of July, reaching roughly 1.5 million people, many of them new to GLP-1 drugs ^[2].

Lilly's broader strategy for Foundayo has focused on widening the pool of patients who can access it rather than only competing on existing users. In the U.S., that effort has been helped by the temporary Medicare GLP-1 Bridge program, which began in July and is estimated to expand coverage by about 35%, opening access to roughly 20 million potential patients ^[2]. Lilly is also preparing a regulatory submission for Foundayo in type 2 diabetes later this year, and for its next-generation obesity drug retatrutide in early 2027 ^[2].

The specific competitive landscape orforglipron will face in China — including which domestic drugmakers are furthest along with their own GLP-1 pills — was not detailed in the sources reviewed for this article and is not yet confirmed. What is documented is that Lilly's other orforglipron trials have kept moving through their own late-stage changes recently: a Phase 3 master protocol testing the drug in obstructive sleep apnea and obesity had its enrollment raised from 600 to 712 participants and was marked completed, with its results timeline also moved four months earlier, according to trial registry tracking ^[1].

Why it matters for patients

For patients in the U.S., a newly registered trial in China does not change access, price or approval status of Foundayo today. The drug is already approved and being prescribed in the U.S., and this filing is about expanding evidence and regulatory footprint elsewhere ^[2]. Still, a larger, more competitive obesity drug market — with reviews underway in dozens of countries — can eventually affect supply, manufacturing priorities, and how quickly companies negotiate pricing or update product labels, since sales in bigger markets can shape corporate investment decisions.

The registration is also a reminder that late-stage trial records shift often and without a public trail of what changed. Enrollment numbers, completion dates and trial status for orforglipron and other GLP-1 drugs have moved multiple times in company registries in just the past several weeks, according to trial monitoring records ^[1]. Patients weighing whether to start or continue a GLP-1 medication may want to know that public trial listings can understate how fluid these programs still are, even for already-approved drugs.

What happens next

The China trial is currently listed as not yet recruiting, so no start date, completion date or results timeline is available yet ^[1]. Separately, Lilly has said it plans to submit Foundayo for a type 2 diabetes indication later this year and expects to submit retatrutide for obesity and overweight in early 2027 ^[2]. No timeline for a Chinese regulatory decision on orforglipron was included in the sources reviewed.